New treatment could save 1,000
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A new method of delivering anti-cancer drugs to patients after bowel cancer surgery might prevent about 1,000 deaths a year in the UK, the Imperial Cancer Research Fund says today.
The new approach, of feeding drugs directly into the liver, through a tube inserted during surgery (portal vein infusion), means that more of the drug reaches this gland than when drugs are delivered in the normal way - by mouth or injecting them into the bloodstream. Reaching the liver is essential because it is the most common site for recurrence of bowel cancer, which kills 18,000 people a year in the UK and is the second leading cause of cancer deaths.
Researchers at the charity's Cancer Studies Unit in Oxford carried out a review of data on 4,000 patients in 10 studies world-wide and found that portal vein infusion appeared to reduce deaths by 5 per cent. Professor Richard Peto, the unit's head, said: "PVI is an unusually convenient cancer treatment. It's given for just one week after surgery and has few major side-effects."
Portal Vein Chemotherapy for Colorectal Cancer, Journal of the National Cancer Institute, 2 April 1997. Annabel Ferriman
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments